Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

ltalian Registry Chronlc PancrEatitis (ITA RECIPE)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
ITARECIPE
Codice EudraCT
NP
Sponsor/Promotore
Associazione Italiana per lo Studio del Pancreas (AISP)
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio internazionale randomizzato per confrontare il sovradosaggio radioterapico intraoperatorio (IORT) rispetto al sovradosaggio radioterapico convenzionale sul letto operatorio dopo chirurgia conservativa in donne con tumore della mammella a rischio alto di recidiva locale

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
TARGIT-B
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Sperimentale
Fase
.
Unità Operativa
Principal Investigator
Sperimentazione in attesa di assegnazione

La cura della persona guarita dal cancro- Valutazione Counselling e Facilitazione- Studio pilota Survey e di coorte

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
cancer survivor
Codice EudraCT
NP
Sponsor/Promotore
LILT (Lega Italiana per la Lotta contro i Tumori)
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Rechallenge con doxorubicina liposomale pegilata in aggiunta alla trabectedina nella recidiva di tumore ovarico: studio prospettico multicentrico (REPRAB study – MITO 36)

Stato
Autorizzato - In attesa di apertura
Codice studio
REPRAB - MITO 36
Codice EudraCT
2017-004690-14
Sponsor/Promotore
Policlinico Universitario A. Gemelli di Roma
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Studio di Fase II sulla somministrazione intratumorale di L19IL2/L19TNF in pazienti affetti da tumori della pelle non-melanoma con lesioni iniettabili.

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
PH-L19IL2TNFBASK-04-21 (IntriNSiC)
Codice EudraCT
2021-006041-36
Sponsor/Promotore
PHILOGEN S.P.A.
Tipologia
Sperimentale
Fase
II
Principal Investigator

Studio di Fase 1/2 volto a valutare la sicurezza e l’efficacia della terapia di combinazione con amivantamab e capmatinib nel carcinoma polmonare non a piccole cellule metastatico non resecabile

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
61186372PANSC2001 (METalmark)
Codice EudraCT
2022-000485-18
Sponsor/Promotore
Janssen-Cilag International NV
Tipologia
Sperimentale
Fase
I / II
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top